Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
OCGN's OCU410 Phase 2 data showed 46% lesion growth reduction in GA, but dose-response inconsistencies and small sample sizes temper enthusiasm. Key catalysts in 2026 include OCU410 full Phase 2 data, OCU410ST interim Stargardt data, and OCU400 Phase 3 top-line results. Despite blockbuster potential, OCGN faces high risk from limited cash runway, lack of partners, and uncertain late-stage trial outcomes. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » Yoshiyoshi Hirokawa/DigitalVision via Getty Images The share price of Malvern, Pennsylvania based Ocugen, Inc. ( OCGN ), a biotech specialising in developing gene therapies to treat eye diseases, fell by nearly 15% in trading yesterday, after the company shared data from More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts drivi
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationGlobeNewswire
- Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]Yahoo! Finance
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial DataGlobeNewswire
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 8/1/25 - In-Line
OCGN
Sec Filings
- 1/15/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- OCGN's page on the SEC website